{"id":"W2276335262","doi":"10.1016/j.jaad.2015.10.043","title":"Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults","year":2016,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":305,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Galderma; Astellas Pharma; Regeneron Pharmaceuticals; Genentech; Celgene; Valeant Pharmaceuticals International; Sanofi; Chugai Pharmaceutical; Pfizer; Amgen","keywords":"Medicine; Dupilumab; Atopic dermatitis; Quality of life (healthcare); Dermatology Life Quality Index; Anxiety; Eczema Area and Severity Index; Depression (economics); Severity of illness; Clinical trial; Generalizability theory; SCORAD; Disease; Internal medicine; Dermatology; Psychiatry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001197859,0.0001795157,0.001701899,0.0002973815,0.0000258226,0.000001782729,0.0003918024,0.0001885488,0.00004046506],"category_scores_gemma":[0.0008133829,0.0001038029,0.0004220741,0.0002860885,0.0008309296,0.00011198,0.0001286587,0.0004102811,0.000005121228],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003476518,"about_ca_system_score_gemma":0.0002411912,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004724002,"about_ca_topic_score_gemma":0.000005350932,"domain_scores_codex":[0.996236,0.0007239476,0.002254339,0.0001878393,0.000371813,0.0002260396],"domain_scores_gemma":[0.9959501,0.0008200378,0.002619967,0.0002518724,0.0001518125,0.0002062348],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4251744,0.009716589,0.3200656,0.0008204366,0.00342385,0.001744377,0.009551568,0.0001279307,0.0135761,0.0004341851,0.04676425,0.1686007],"study_design_scores_gemma":[0.3767871,0.006929406,0.5045292,0.006914364,0.001367607,0.008866151,0.002219104,0.0005665753,0.07377686,0.0085753,0.008732768,0.0007355859],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9767566,0.0006997944,0.00007067336,0.02173896,0.0002255152,0.0003849536,0.00005130515,0.000004790078,0.0000673547],"genre_scores_gemma":[0.9971086,0.000559444,0.0005495117,0.001675686,0.00007589868,0.000006285187,0.000001258512,0.00001383114,0.000009527637],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1844636,"threshold_uncertainty_score":0.4232959,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02186583079233416,"score_gpt":0.3439859349347897,"score_spread":0.3221201041424555,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}